Accuracy of PET-CT for detecting recurrent ovarian cancer is high

The accuracy of PET-CT for detecting recurrent ovarian cancer is high, more accurate even than either CT or PET alone, says a new study by researchers from Massachusetts General Hospital in Boston.

For the study, the researchers reviewed 54 body CT, PET and PET-CT examinations on 53 patients with ovarian cancer who were being evaluated for tumor recurrence. The researchers found that PET-CT demonstrated an improved accuracy (49/53, 92%) over CT alone (44/53, 83%) and over PET alone (41/53, 77%).

"We undertook this study because PET-CT is a hot and emerging imaging technique, and its use continues to be evaluated for many indications in the abdomen and pelvis. Also, on CT it is difficult many times to detect ovarian cancer recurrence because of the presence of certain metastatic deposits," said Sunit Sebastian, MD, who is currently at Emory University School of Medicine and is lead author on the study.

According to the researchers, the results of their study could mean earlier and more definitive detection of recurrent ovarian cancer. "When you combine the advantages of the excellent anatomical depiction that CT gives us and the amount of functional information that PET give us, doctors are better able to monitor cancer patients and manage their treatment accordingly," said Dr. Sunit Sebastian.

The full results of the study were presented during the American Roentgen Ray Society Annual Meeting in Vancouver, BC.

http://www.arrs.org

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Study reveals how cancer cells evade chemotherapy in low-glucose environments